Papillon CXB in the United States

Papillon CXB in the United States
Redefining Rectal Cancer Care in North America

Interest in Papillon Contact X-ray Brachytherapy (CXB) is experiencing a strong resurgence across North America, driven by emerging clinical evidence and increased focus on organ-preserving treatment approaches.

Recent randomised clinical trials, including the OPERA Trial, have played a key role in reshaping clinical perspectives. Alongside this, guidance from the National Institute for Health and Care Excellence (NICE) in the UK has further reinforced confidence in Papillon CXB as a viable non-surgical option for selected rectal cancer patients.

While Contact X-ray Brachytherapy was first developed in the mid-20th century, its adoption was historically limited by the rise of conventional surgical approaches. Today, advances in technology and clinical understanding have positioned Papillon CXB as a sophisticated, non-invasive alternative—supporting organ preservation, improving patient quality of life, and offering favourable long-term healthcare economics.

Clinical trials and evaluation programmes are now underway at several leading centres of excellence across North America. Ariane Medical Systems is proud to collaborate with these institutions and looks forward to supporting the transition from clinical evaluation to broader implementation.

For further information, please contact:

Mark Davies-Cousins
VP International Sales
📞 +44 (0) 7940 359998
✉️ mark.davies@arianemedicalsystems.com